Search Results for “Quiz 2024 EMC D-PDM-DY-23: Dell PowerProtect Data Manager Deploy 2023 Exam Updated Vce Download 🌋 Copy URL ➥ www.pdfvce.com 🡄 open and search for ⇛ D-PDM-DY-23 ⇚ to download for free 🥇Latest D-PDM-DY-23 Test Testking” – Page 13

EUFOREUM Berlin 2023: optimizing care for type 2 inflammatory diseases from clinic to AI: a pediatric focus

595.

Conti, D. M.⁺, Backer, V., Beyer, K., Bjermer, L., Chaker, A., Dramburg, S., Gaga, M., Gappa, M., Gevaert, P., Hamelmann, E., Hellings, P. W., Jesenak, M., Kopp, M., Maurer, M., Podesta, M., Ryan, D., Scadding, G., Wüstenberg, E., Wahn, U., and Lau, S.: EUFOREUM Berlin 2023: optimizing care for type 2 inflammatory diseases from clinic to AI: a pediatric focus. Pediatr. Allergy Immunol. 2024: 35; e14183. IF: TBD (IF 2023: 4.30)

o.594

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the icatibant outcome survey, a cohort observational study

302

Caballero, T.+, Zanichelli, A., Aberer, W., Maurer, M. Longhurst, H. J., Bouillet, L., and Andresen, I.: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the icatibant outcome survey, a cohort observational study. Clin. Transl. Allergy 2018: 8; 11. IF: 4.23

34	Metz, M., Botchkarev, V. A., Botchkareva, N. V., Welker, P., Tobin, D., Knop, J., Maurer, M.+ and Paus, R.: Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Exp. Dermatol. 2004: 13; 273-281. IF: 1.7

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcɛRI-positive cells in the skin

269

Metz, M., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Kangas, M., Ashton-Chess, J., Jarvis, P., Georgiou, P., Canvin, J., Hillenbrand, R., Erpenbeck, V. J., and Maurer, M.+: Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcɛRI-positive cells in the skin. Theranostics 2017: 7; 1266-1276. IF: 8.54

326	Riedl, M.+, Farkas, H., Bernstein, J. A., Bouillet, L., Sheridan, W. P., and Maurer, M.: Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy 2018: 73; 1871-1880. IF: 6.77

120.	Kolkhir, P., André, F., Church, M. K., Maurer, M., and Metz, M.: Potential blood biomarkers in chronic spontaneous urticaria. Clin. Exp. Allergy 2017: 47; 19-36. IF: 5.16

r.120

403.	Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Rujitharanawong, C., Kiratiwongwan, R., Jantanapornchai, N., Hawro, T., and Maurer, M.⁺: Symptomatic dermographism: a systematic review of treatment options. J. Allergy Clin. Immunol. Pract. 2020: 8; 3141-3161. IF: 8.86

o.403

351	*Maurer, M.+*, Raap, U., Staubach, P., Richter-Huhn, G., Bauer, A., Oppel, E. M., Hillen, U., Bäumer, D., Reinhardt, M., and Chapman-Rothe, N.: Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin. Exp. Allergy 2019: 49; 655-662. IF: 4.22

o.351

Ligelizumab for Chronic Spontaneous Urticaria

360

Maurer, M.+, Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hebert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., Staubach, P., Wedi, B., Löffler, J., Barve, A., Kobayashi, K., Hua, E., Severin, T., and Janocha, R.: Ligelizumab for chronic spontaneous urticaria. New Engl. J. Med. 2019: 381; 1321-1332. IF: 74.70

o.360

575.	Salameh, P., Gutsche, A., Aulenbacher, F., Buttgereit, T., Weller, K., Siebenhaar, F., and Maurer, M.⁺: Urticaria control test real-world performance: a post hoc analysis. Allergy 2024: 79; 229-232. IF: TBD (IF 2023: 12.60)

Results